In this article by Dr. Bettina Hamelin of Innovative Medicines Canada, readers learn about the risks of replacing private drug plans with a limited national formulary and how that could reduce access to innovative treatments. The piece explains concern over longer wait times and fewer treatment options if the system is narrowed. It also shows how provinces like Prince Edward Island used a “fill-the-gaps” model to expand access without undermining what already works for most people.